HSBC Holdings’s Beam Therapeutics BEAM Stock Holding History

HSBC Holdings’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-13,021	Closed	-$226K	–	2730
2025 Q2	$226K	Sell	13,021 -2,317	-15%	-$40.3K	﹤0.01%	2623
2025 Q1	$285K	Sell	15,338 -11,176	-42%	-$293K	﹤0.01%	2412
2024 Q4	$666K	Buy	26,514 +11,327	+75%	+$289K	﹤0.01%	2012
2024 Q3	$371K	Buy	15,187 +846	+6%	+$21.9K	﹤0.01%	2196
2024 Q2	$332K	Buy	+14,341	New	+$352K	﹤0.01%	2219
2023 Q4	–	Sell	-17,261	Closed	-$416K	–	2730
2023 Q3	$416K	Sell	17,261 -16,461	-49%	-$441K	﹤0.01%	2059
2023 Q2	$1.09M	Buy	33,722 +17,384	+106%	+$564K	﹤0.01%	1685
2023 Q1	$501K	Buy	+16,338	New	+$645K	﹤0.01%	2042
2022 Q3	–	Sell	-5,671	Closed	-$221K	–	2936
2022 Q2	$221K	Buy	+5,671	New	+$225K	﹤0.01%	2827

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

HSBC Holdings's BEAM Position: Q3 2025 in Review

HSBC Holdings sold out of Beam Therapeutics (BEAM) in Q3 2025, closing a stake of 13,021 shares — an estimated $226K sold.

HSBC Holdings first reported a position in BEAM in Q2 2022 and held it in 9 quarters. The position peaked at $1.09M in Q2 2023. 219 funds tracked by Wall St. Rank hold BEAM as of Q3 2025.

HSBC Holdings reported no remaining Beam Therapeutics position as of Q3 2025 after selling out during the quarter.
HSBC Holdings sold 13,021 Beam Therapeutics shares in Q3 2025, an estimated $226K.
HSBC Holdings first reported a position in Beam Therapeutics in Q2 2022 and held it in 9 quarters.
HSBC Holdings's Beam Therapeutics position peaked at $1.09M in Q2 2023.
219 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2025.

Based on HSBC Holdings's 13F filing for Q3 2025, filed 13 Nov 2025.